China approves two potential coronavirus vaccines for trials

In the global race to produce vaccines for the novel coronavirus, China has launched human trials on two more potential candidates.
One of the vaccine candidates was developed by the Wuhan Institute of Biological Products and the China National Pharmaceutical Group (Sinopharm) while the other was developed by Sinovac Research & Development Co., Ltd., a Beijing-based company that was involved in vaccine development for SARS back in 2003.
Around the world, at least 70 potential vaccines are under development with three already undergoing human trials, according to the World Health Organization.

Both of Chinas latest efforts are inactivated vaccines, meaning that they are made from virus particles that have been killed, rather than just weakened, so there is no danger from infection, though they tend to trigger a weaker immune response so multiple doses may be required.

For approval, vaccines in China typically require at least three phases of human trials. Sinopharms first two phases wont be completed until November 2021, according to Caixin.
With the Covid-19 virus claiming more than 119,000 lives across the globe, humanity is hoping for an approved vaccine by next year.



Subscribe by Email

Follow Updates Articles from This Blog via Email

No Comments